Chronic Myeloid Leukemia: Navigating Drug Resistance and Optimizing Care

Program Description
Chronic myeloid leukemia (CML) is a myeloproliferative cancer that is characterized by an increased number of immature white blood cells in patients’ blood and bone marrow. Though tyrosine kinase inhibitors (TKIs) targeted to BCR::ABL-1 have improved patient survival, several limitations to their use exist, including the potential for drug resistance, TKI-related toxicities, and suboptimal treatment adherence. Kinase-dependent and kinase-independent mechanisms in the BCR::ABL fusion gene cause resistance to certain therapies, and oncology pharmacists are poised to optimize treatment of CML for patients who develop TKI resistance by improving therapy selection and staying informed of updates in recent clinical evidence. This program will provide a summary of clinical evidence for approved and investigational TKIs in the treatment of CML. Guideline-recommended management strategies to support timely recognition of inadequate response or resistance to TKIs as well as mitigate adverse effects of therapy will be discussed.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: October 26, 2023
Expiration date: December 26, 2023

Time to complete activity: 1.0 hour

Learner level: Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify factors influencing tyrosine kinase inhibitor (TKI) resistance in chronic myeloid leukemia (CML) and methods for effective treatment
• Personalize treatment for patients with CML who have developed resistance to frontline TKI therapy considering patient- and disease-specific characteristics
• Employ strategies for managing toxicities associated with TKIs, including dosing, monitoring, and use of supportive care measures

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-349-L01-P. The activity is available for CE credit through December 26, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Jordan Snyder, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy Morris, PharmD, BCOP; Angelica Archibald; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms